Search results for " signal transduction inhibitors"

showing 2 items of 2 documents

Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells.

2019

Abstract Pancreatic cancer is devastating cancer worldwide with few if any truly effective therapies. Pancreatic cancer has an increasing incidence and may become the second leading cause of death from cancer. Novel, more effective therapeutic approaches are needed as pancreatic cancer patients usually survive for less than a year after being diagnosed. Control of blood sugar levels by the prescription drug metformin in diseases such as diabetes mellitus has been examined in association with pancreatic cancer. While the clinical trials remain inconclusive, there is hope that certain diets and medications may affect positively the outcomes of patients with pancreatic and other cancers. Other…

0301 basic medicineCancer ResearchSettore MED/09 - Medicina Internaendocrine system diseasesBerberineSignal transduction inhibitorsBlood sugarPharmacologyAMP-Activated Protein KinasesBerberine; PDAC; Signal transduction inhibitors; TP5303 medical and health scienceschemistry.chemical_compound0302 clinical medicineBerberineMETFORMINAPancreatic cancerDiabetes mellitusGeneticsmedicineHumansTP53Signal transduction inhibitorMolecular BiologyCell Proliferationbusiness.industryPDACCancerAMPKmedicine.diseaseMetforminMetforminNeoplasm ProteinsPancreatic Neoplasms030104 developmental biologychemistry030220 oncology & carcinogenesisCancer cellMolecular Medicinebusinessmedicine.drugAdvances in biological regulation
researchProduct

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.

2012

Hepatocellular carcinoma (HCC) is the most common liver cancer, accounting for 90% of primary liver cancers. In the last decade it has become one of the most frequently occurring tumors worldwide and is also considered to be the most lethal of the cancer systems, accounting for approximately one third of all malignancies. Although the clinical diagnosis and management of early-stage HCC has improved significantly, HCC prognosis is still extremely poor. Furthermore, advanced HCC is a highly aggressive tumor with a poor or no response to common therapies. Therefore, new effective and well-tolerated therapy strategies are urgently needed. Targeted therapies have entered the field of anti-neopl…

SorafenibOncologymedicine.medical_specialtyPathologyCarcinoma Hepatocellularmedicine.medical_treatmentReviewsAntineoplastic AgentsDiseasesignal transduction inhibitorsModels BiologicalTargeted therapyInternal medicinemedicineCarcinomacancerAnimalsHumansMolecular Targeted TherapyHCCneoplasmsCause of deathbusiness.industryTherapies InvestigationalLiver NeoplasmsCancerDrugs Investigationalmedicine.diseasetargeted therapyVEGFdigestive system diseasesOncologyHepatocellular carcinomaRas/Raf/MEK/ERKHCC targeted therapy VEGF Ras/Raf/MEK/ERK PI3K/Akt/PTEN/mTOR signal transduction inhibitors cancPI3K/Akt/PTEN/mTORLiver cancerbusinessmedicine.drugSignal Transduction
researchProduct